SMA Press

Following the approval of Evrysdi, Roche released an article describing its partnership with the SMA Foundation and PTC Therapeutics to develop the drug. To read the article, please visit: https://www.roche.com/partnering/spinal-muscular-atrophy-sma-together.htm

Arya Singh, an SMA patient and Yale University student, was featured in a New Haven Register article on September 19th. In the article, Singh describes the challenges she faces as a patient and her experiences in clinical trials. To view the article, please visit: https://www.ctinsider.com/news/nhregister/article/This-Yale-student-won-t-let-a-rare-genetic-15579131.php?src=nhrhpcp To view a photo essay for the article, please visit:…

In August, SMA News Today published a series of articles on the discovery and development of Evrysdi, the first and only oral medicine for SMA approved by the FDA. The articles cover a range of topics including the role of the SMA Foundation in drug development, the experiences of patients taking Evrysdi, and the future…

As part of its “Collaborations That Transform” webinar series, WuXi AppTec hosted three panels of distinguished SMA experts, representing patient, industry and physician perspectives. The panelists discussed the current state of SMA therapies and the promise of the next generation of treatment approaches. To view the webinar please visit: https://wxpress.wuxiapptec.com/webinar-sma/

The SMA Foundation’s partners, Roche and PTC Therapeutics, announced today that Evrysdi™ (risdiplam) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Spinal Muscular Atrophy (SMA) in adults and children two months and older. Evrysdi showed clinically meaningful improvements in motor function across two clinical trials covering a broad range…